DE60204142T2 - Zubereitungen mit olopatadin zur topischen anwendung - Google Patents
Zubereitungen mit olopatadin zur topischen anwendung Download PDFInfo
- Publication number
- DE60204142T2 DE60204142T2 DE60204142T DE60204142T DE60204142T2 DE 60204142 T2 DE60204142 T2 DE 60204142T2 DE 60204142 T DE60204142 T DE 60204142T DE 60204142 T DE60204142 T DE 60204142T DE 60204142 T2 DE60204142 T2 DE 60204142T2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- polyvinylpyrrolidone
- olopatadine
- weight
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims description 5
- 230000000699 topical effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 64
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 52
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 51
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 51
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims description 47
- 239000000243 solution Substances 0.000 claims description 45
- 229960004114 olopatadine Drugs 0.000 claims description 44
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 claims description 13
- 229940005642 polystyrene sulfonic acid Drugs 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 230000000172 allergic effect Effects 0.000 claims description 9
- 208000010668 atopic eczema Diseases 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
- 150000002978 peroxides Chemical class 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000009472 formulation Methods 0.000 description 14
- 239000008213 purified water Substances 0.000 description 11
- 239000011550 stock solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 6
- 229960000686 benzalkonium chloride Drugs 0.000 description 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 6
- -1 inorganic acid salts Chemical class 0.000 description 6
- 229960005426 doxepin Drugs 0.000 description 5
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229920001684 low density polyethylene Polymers 0.000 description 3
- 239000004702 low-density polyethylene Substances 0.000 description 3
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940100656 nasal solution Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100453960 Drosophila melanogaster klar gene Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 229940073464 benzododecinium bromide Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940031663 carbomer-974p Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940023485 nasal product Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 229940097078 patanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30131501P | 2001-06-27 | 2001-06-27 | |
| US301315P | 2001-06-27 | ||
| PCT/US2002/019417 WO2003002093A1 (en) | 2001-06-27 | 2002-06-19 | Olopatadine formulations for topical administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60204142D1 DE60204142D1 (de) | 2005-06-16 |
| DE60204142T2 true DE60204142T2 (de) | 2005-10-06 |
Family
ID=23162841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60204142T Expired - Lifetime DE60204142T2 (de) | 2001-06-27 | 2002-06-19 | Zubereitungen mit olopatadin zur topischen anwendung |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6995186B2 (https=) |
| EP (1) | EP1399127B1 (https=) |
| JP (5) | JP4827374B2 (https=) |
| KR (1) | KR100884711B1 (https=) |
| CN (1) | CN1211125C (https=) |
| AR (1) | AR034619A1 (https=) |
| AT (1) | ATE295149T1 (https=) |
| AU (1) | AU2002310461B2 (https=) |
| BR (1) | BRPI0210707B8 (https=) |
| CA (1) | CA2447924C (https=) |
| DE (1) | DE60204142T2 (https=) |
| DK (1) | DK1399127T3 (https=) |
| ES (1) | ES2238574T3 (https=) |
| GC (1) | GC0000397A (https=) |
| MX (1) | MXPA03011947A (https=) |
| PL (1) | PL205565B1 (https=) |
| PT (1) | PT1399127E (https=) |
| TW (1) | TWI231759B (https=) |
| WO (1) | WO2003002093A1 (https=) |
| ZA (1) | ZA200308771B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100055152A1 (en) * | 2008-08-26 | 2010-03-04 | Trutek Corporation | Antihistamine and antihistamine-like nasal application, products, and method |
| US7977376B2 (en) | 2001-06-27 | 2011-07-12 | Novartis Ag | Olopatadine formulations for topical nasal administration |
| TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
| US20050209312A1 (en) * | 2004-03-19 | 2005-09-22 | Bausch & Lomb Incorporated | Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative |
| US20070275853A1 (en) * | 2004-04-08 | 2007-11-29 | Kyowa Hakko Kogyo Co., Ltd. | Solid Products with Improved Stability and Method for Producing the Same |
| US20070225356A1 (en) * | 2004-04-21 | 2007-09-27 | Kyowa Hakko Kogo Co., Ltd | Preventive and/or Therapeutic Agent for Chronic Sinusitis |
| ZA200610350B (en) * | 2004-06-28 | 2008-12-31 | Alcon Inc | Topical formulations for treating allergic diseases |
| AU2005309951B2 (en) * | 2004-11-24 | 2011-07-07 | Alcon, Inc. | Method of delivering nasal spray |
| WO2006097458A1 (en) * | 2005-03-15 | 2006-09-21 | Nycomed Gmbh | Novel combination |
| JP5315051B2 (ja) * | 2005-07-08 | 2013-10-16 | 千寿製薬株式会社 | オロパタジンを含む眼科用経皮吸収型製剤 |
| US20070077302A1 (en) * | 2005-09-30 | 2007-04-05 | Azaam Alli | Methods for stabilizing ophthalmic compositions |
| US20080114076A1 (en) * | 2006-11-09 | 2008-05-15 | Alcon Manufacturing Ltd. | Punctal plug comprising a water-insoluble polymeric matrix |
| TWI409081B (zh) * | 2006-11-09 | 2013-09-21 | Alcon Res Ltd | 用於藥物輸送之水不溶性聚合物基質 |
| MX2009006146A (es) * | 2006-12-18 | 2009-06-19 | Alcon Res Ltd | Dispositivos y metodos para la administracion de farmacos oftalmicos. |
| WO2008093358A2 (en) * | 2007-01-29 | 2008-08-07 | Sun Pharmaceutical Industries Limited | Aqueous topical solution containing olopatadine |
| KR20100014858A (ko) * | 2007-02-07 | 2010-02-11 | 알콘, 인코퍼레이티드 | 국소 비강 투여용 올로파타딘 제제 |
| WO2008120249A1 (en) * | 2007-03-30 | 2008-10-09 | Sifi S.P.A. | Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use |
| TW200902025A (en) * | 2007-04-11 | 2009-01-16 | Alcon Res Ltd | Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis |
| EP2189157A4 (en) * | 2007-09-06 | 2012-10-31 | Kyowa Hakko Kirin Co Ltd | EYE DROPPING WITH DIBENZO [b, e] OXEPINE DERIVATIVE |
| CA2723954A1 (en) * | 2008-05-19 | 2009-11-26 | Alcon Research, Ltd. | Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer |
| AU2009288566A1 (en) * | 2008-08-26 | 2010-03-11 | Trutek Corp. | Electrostatically charged mask filter products and method for increased filtration efficiency |
| KR20110056526A (ko) * | 2008-08-28 | 2011-05-30 | 트루텍 코프. | 항히스타민 및 유사-항히스타민 코 외용약, 생성물 및 방법 |
| US9458198B1 (en) | 2009-06-26 | 2016-10-04 | Shire Orphan Therapies Gmbh | Cyclic peptide-based NPR-B agonists |
| EP2453872B1 (en) * | 2009-07-17 | 2013-08-21 | Alcon Research, Ltd. | Olopatadine nasal spray regimen for children |
| WO2011027322A1 (en) | 2009-09-03 | 2011-03-10 | Ranbaxy Laboratories Limited | Extended release dosage form containing olopatadine for oral administration |
| EP2480247B1 (en) * | 2009-09-25 | 2020-02-12 | Shire Orphan Therapies GmbH | Novel npr-b agonists |
| US8551938B2 (en) * | 2009-09-25 | 2013-10-08 | Alcon Research, Ltd. | NPR-B agonists |
| US20110082145A1 (en) * | 2009-10-01 | 2011-04-07 | Alcon Research, Ltd. | Olopatadine compositions and uses thereof |
| AR078446A1 (es) | 2009-12-18 | 2011-11-09 | Alcon Res Ltd | Agonistas de npr-b. uso. |
| WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
| US20120022149A1 (en) * | 2010-07-21 | 2012-01-26 | Chowhan Masood A | Pharmaceutical composition with enhanced solubility characteristics |
| EP2944319A1 (en) * | 2010-11-08 | 2015-11-18 | Arava Bio-Tech Ltd. | Buffered ophthalmic compositions and use thereof |
| TWI544922B (zh) * | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
| CN102885767A (zh) * | 2012-11-02 | 2013-01-23 | 江苏吉贝尔药业有限公司 | 一种新的盐酸奥洛他定滴眼液及其制备方法 |
| EP3576770A1 (en) | 2017-02-01 | 2019-12-11 | Shire Human Genetic Therapies, Inc. | Compounds and compositions for the treatment of ophthalmic disorders |
| JP7037349B2 (ja) * | 2017-06-23 | 2022-03-16 | 参天製薬株式会社 | 水溶性粘稠化剤を含有する医薬組成物 |
| WO2018235935A1 (ja) * | 2017-06-23 | 2018-12-27 | 参天製薬株式会社 | 水溶性粘稠化剤を含有する医薬組成物 |
| CN114980881A (zh) * | 2019-12-06 | 2022-08-30 | 东兴药品工业株式会社 | 包含奥洛他定的鼻用组合物 |
| US20230145529A1 (en) * | 2020-03-31 | 2023-05-11 | Santen Pharmaceutical Co., Ltd. | Silver salt-containing ophthalmic aqueous composition filled in resin container |
| CN111700860A (zh) * | 2020-07-09 | 2020-09-25 | 浙江尖峰药业有限公司 | 盐酸奥洛他定滴眼液及其制备方法 |
| CN119318630B (zh) * | 2024-10-16 | 2025-08-22 | 苏州欧康维视生物科技有限公司 | 一种阿托品药物组合物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4370324A (en) | 1980-09-17 | 1983-01-25 | Bernstein Joel E | Method and composition for treating and preventing irritation of the eyes |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| US4749700A (en) | 1984-10-23 | 1988-06-07 | Nastech Pharmaceutical Co, Inc. | Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same |
| US4923892A (en) | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
| GB8520662D0 (en) | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
| JPS6310784A (ja) | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | 抗アレルギー剤 |
| ATE84968T1 (de) | 1987-11-13 | 1993-02-15 | Asta Medica Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge. |
| IT1250691B (it) | 1991-07-22 | 1995-04-21 | Giancarlo Santus | Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac. |
| JP3662944B2 (ja) | 1993-08-24 | 2005-06-22 | 協和醗酵工業株式会社 | 点鼻剤 |
| US5897858A (en) | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| US5641805A (en) | 1995-06-06 | 1997-06-24 | Alcon Laboratories, Inc. | Topical ophthalmic formulations for treating allergic eye diseases |
| EP1014979A4 (en) | 1997-06-09 | 2003-08-20 | Bridge Pharma Inc | CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE |
| WO2000003705A1 (en) | 1998-07-14 | 2000-01-27 | Alcon Laboratories, Inc. | Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization |
| US6146622A (en) | 1998-10-27 | 2000-11-14 | Alcon Laboratories, Inc. | Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions |
| DK1124535T3 (da) * | 1998-10-27 | 2003-01-06 | Alcon Lab Inc | Konserverende system til topisk indgivelige farmaceutiske præparater indeholdende en fedtsyre/aminosyresæbe |
| US6274626B1 (en) * | 1998-12-22 | 2001-08-14 | Bausch & Lomb Incorporated | Pheniramine-containing compositions and method for treating allergic responses |
| US6174914B1 (en) | 1999-06-15 | 2001-01-16 | Alcon Laboratories, Inc. | Method of inhibiting cytokine release from human ocular cells |
| BR0014117A (pt) | 1999-09-21 | 2002-05-14 | Alcon Lab Inc | Uso de sabÈes de acido graxo/aminoácido para aumentar a eficácia antimicrobiana de composições farmacêutica tópicas |
| MXPA02005007A (es) | 1999-11-18 | 2004-08-12 | Alcon Inc | Uso de un antagonista h1 y un esteroide inocuo para tratar condiciones oculares. |
| DE60109742T2 (de) * | 2000-01-25 | 2005-08-18 | Alcon Inc. | Antiallergische ophthalmische zubereitungen, geeignet zur anwendung mit kontaktlinsen |
| PE20020578A1 (es) | 2000-10-10 | 2002-08-14 | Upjohn Co | Una composicion de antibiotico topico para el tratamiento de infecciones oculares |
| TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
| BR0316203A (pt) | 2002-11-12 | 2005-10-04 | Alcon Inc | Uso de um agente antialérgico e um esteróide para tratar rinite alérgica |
-
2002
- 2002-06-18 TW TW091113234A patent/TWI231759B/zh not_active IP Right Cessation
- 2002-06-19 WO PCT/US2002/019417 patent/WO2003002093A1/en not_active Ceased
- 2002-06-19 US US10/175,106 patent/US6995186B2/en not_active Expired - Lifetime
- 2002-06-19 KR KR1020037014821A patent/KR100884711B1/ko not_active Expired - Lifetime
- 2002-06-19 DE DE60204142T patent/DE60204142T2/de not_active Expired - Lifetime
- 2002-06-19 BR BRPI0210707A patent/BRPI0210707B8/pt not_active IP Right Cessation
- 2002-06-19 PL PL367780A patent/PL205565B1/pl unknown
- 2002-06-19 AU AU2002310461A patent/AU2002310461B2/en not_active Expired
- 2002-06-19 EP EP02737539A patent/EP1399127B1/en not_active Expired - Lifetime
- 2002-06-19 PT PT02737539T patent/PT1399127E/pt unknown
- 2002-06-19 MX MXPA03011947A patent/MXPA03011947A/es active IP Right Grant
- 2002-06-19 AT AT02737539T patent/ATE295149T1/de active
- 2002-06-19 DK DK02737539T patent/DK1399127T3/da active
- 2002-06-19 CN CNB028120434A patent/CN1211125C/zh not_active Expired - Lifetime
- 2002-06-19 ES ES02737539T patent/ES2238574T3/es not_active Expired - Lifetime
- 2002-06-19 CA CA002447924A patent/CA2447924C/en not_active Expired - Lifetime
- 2002-06-19 JP JP2003508332A patent/JP4827374B2/ja not_active Expired - Lifetime
- 2002-06-22 GC GCP20022092 patent/GC0000397A/en active
- 2002-06-24 AR ARP020102365A patent/AR034619A1/es not_active Application Discontinuation
-
2003
- 2003-11-11 ZA ZA2003/08771A patent/ZA200308771B/en unknown
-
2005
- 2005-03-15 US US11/079,996 patent/US7402609B2/en not_active Expired - Lifetime
-
2009
- 2009-03-02 JP JP2009048628A patent/JP2009114213A/ja not_active Withdrawn
-
2010
- 2010-03-24 JP JP2010069010A patent/JP2010150292A/ja not_active Withdrawn
-
2012
- 2012-02-21 JP JP2012035170A patent/JP5328947B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-25 JP JP2013061887A patent/JP2013127005A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60204142T2 (de) | Zubereitungen mit olopatadin zur topischen anwendung | |
| DE69521686T2 (de) | Ophtalmische zubereitung niedriger viskosität | |
| DE60126321T2 (de) | Gelsystem zur ocularen verabreichung von arzneimitteln | |
| DE69129078T2 (de) | Aminosteroide zur Verwendung in der Augenheilkunde | |
| DE69212850T2 (de) | Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen | |
| DE69527422T2 (de) | Ophthalmologische zusammensetzung, die ein ionenempfindliches polymer und ein anorganisches salz in einem verhältnis enthält, das eine niedrige viskosität ergibt | |
| KR101821518B1 (ko) | 고농도 올로파타딘 안과용 조성물 | |
| DE68902649T2 (de) | Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen. | |
| AU2002310461A1 (en) | Olopatadine formulations for topical administation | |
| DE202009019116U1 (de) | Wässrige pharmazeutische Zusammensetzungen, die Borat-Polyol-Komplexe enthalten | |
| DE2708152A1 (de) | Pharmazeutisches traegermaterial und dessen verwendung | |
| DE69825128T2 (de) | Verwendung von azithromycin zur topischen behandlung von augeninfektionen | |
| DE69526369T2 (de) | Entzündungshemmende augentropfen | |
| US6281224B1 (en) | Pranoprofen eyedrops containing organic amine | |
| DE69323202T2 (de) | Ophthalmologische zubereitungen | |
| DE69208941T2 (de) | Augenpräparate mit verlängerter Freigabe | |
| DE60002719T2 (de) | Ophthalmische zusammensetzungen in form wässriger gele | |
| DE69902738T2 (de) | Ophthalmische zubereitung | |
| DE69819900T2 (de) | Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil | |
| DE60132325T2 (de) | Ophthalmische lösung | |
| DE69229688T2 (de) | Ophthalmische Zusammensetzungen, die Kombinationen von einem Carboanhydrase-Inhibitor und einem Beta-adrenergischen Antagonist enthalten | |
| DE69220484T2 (de) | Augenarzneimittel enthaltend Timolol Hemihydrat | |
| DE69415757T2 (de) | Zusammensetzung zur Vorbeugung und Behandlung von Myopie | |
| US4694022A (en) | Fatty acid salts of betaxolol useful in the treatment of glaucoma | |
| DE2461570A1 (de) | Antibakterielle pharmazeutische ohren- und augenformulierungen und verfahren zu ihrer herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |